Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination With Bevacizumab for Patients With Advanced Cancers.

Trial Profile

A Phase I Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination With Bevacizumab for Patients With Advanced Cancers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ridaforolimus (Primary) ; Bevacizumab
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 26 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 23 Sep 2009 Results have been presented at the Joint Multidisciplinary Congress of the 15th annual European Cancer Organisation (ECCO) and the 34th annual European Society of Medical Oncology (ESMO), according to a ARIAD pharmaceuticals media release.
  • 28 Jul 2009 Status changed from recruiting to active, no longer recruiting. Information reported in an ARIAD Pharmaceuticals media release states patient enrolment has been completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top